John Maraganore
CIK 1180432 · Chief Executive Officer · last filed 2026-10-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ALNY price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
CAMBRIDGE, MA 02139
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RAPP | Director | 8,239 | $27.69 | $228.1K | $248.9K | 3 | 2026-10-22 |
| CTY | Director | 1,789,199 | — | — | $0 | 1 | 2026-10-19 |
| TAK | Director | 13,800 | $20.32 | $280.3K | $0 | 1 | 2026-07-06 |
| KYMR | Director | — | $118.07 | — | $0 | 5 | 2026-06-25 |
| BEAM | Director | — | $24.51 | — | $0 | 6 | 2026-06-05 |
| COAG | Director | 35,948 | $37.78 | $1.36M | $0 | 1 | 2026-05-04 |
| PROK | Director | — | $1.48 | — | $0 | 1 | 2023-07-03 |
| AGIO | Director | 30,028 | $37.16 | $1.12M | -$1.80M | 18 | 2022-06-23 |
| ALNY | Chief Executive Officer | 231,115 | $225.27 | $52.06M | -$114.58M | 77 | 2021-12-23 |
| bluebird bio, Inc. (BLUE) Delisted | Director | 1,236 | $4.97 | $6.1K | -$4.68M | 9 | 2017-09-18 |
| Regulus Therapeutics Inc. (RGLS) Delisted | Director | 51,254 | $8.16 | $418.2K | $0 | 1 | 2012-10-11 |
Recent Filings · Page 9 of 13
124 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-12-04 | ALNY | Mixed | — | -$5.38M | EDGAR |
| 2015-11-20 | ALNY | Mixed | +10,564 | -$5.19M | EDGAR |
| 2015-06-25 | AGIO | Grant (A) | — | $0 | EDGAR |
| 2015-06-17 | AGIO | Gift (G) | −410 | $0 | EDGAR |
| 2015-06-08 | bluebird bio, Inc. (BLUE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-05-05 | ALNY | Grant (A) | — | $0 | EDGAR |
| 2015-04-30 | AGIO | Gift (G) | −515 | $0 | EDGAR |
| 2015-01-28 | ALNY | Buy (P) | +10,000 | $950.0K | EDGAR |
| 2014-12-22 | bluebird bio, Inc. (BLUE) Delisted | Buy (P) | +2,352 | $199.9K | EDGAR |
| 2014-12-18 | AGIO | Buy (P) | +1,806 | $200.0K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.